Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2011 1
2012 3
2013 1
2015 1
2016 1
2019 1
2020 1
2021 1
2022 2
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial.
Bol KF, Schreibelt G, Bloemendal M, van Willigen WW, Hins-de Bree S, de Goede AL, de Boer AJ, Bos KJH, Duiveman-de Boer T, Olde Nordkamp MAM, van Oorschot TGM, Popelier CJ, Pots JM, Scharenborg NM, van de Rakt MWMM, de Ruiter V, van Meeteren WS, van Rossum MM, Croockewit SJ, Koeneman BJ, Creemers JHA, Wortel IMN, Angerer C, Brüning M, Petry K, Dzionek A, van der Veldt AA, van Grünhagen DJ, Werner JEM, Bonenkamp JJ, Haanen JBAG, Boers-Sonderen MJ, Koornstra RHT, Boomsma MF, Aarntzen EHJ, Gotthardt M, Nagarajah J, de Witte TJM, Figdor CG, de Wilt JHW, Textor J, de Groot JWB, Gerritsen WR, de Vries IJM. Bol KF, et al. Among authors: de goede al. Nat Commun. 2024 Feb 23;15(1):1632. doi: 10.1038/s41467-024-45358-0. Nat Commun. 2024. PMID: 38395969 Free PMC article. Clinical Trial.
Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies.
van Putten EHP, Kleijn A, van Beusechem VW, Noske D, Lamers CHJ, de Goede AL, Idema S, Hoefnagel D, Kloezeman JJ, Fueyo J, Lang FF, Teunissen CE, Vernhout RM, Bakker C, Gerritsen W, Curiel DT, Vulto A, Lamfers MLM, Dirven CMF. van Putten EHP, et al. Among authors: de goede al. Clin Cancer Res. 2022 Apr 14;28(8):1572-1585. doi: 10.1158/1078-0432.CCR-21-3324. Clin Cancer Res. 2022. PMID: 35176144 Free PMC article. Clinical Trial.
Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma.
Bol KF, van den Bosch T, Schreibelt G, Mensink HW, Keunen JE, Kiliç E, Japing WJ, Geul KW, Westdorp H, Boudewijns S, Croockewit SA, van Rossum MM, de Goede AL, Naus NC, van der Graaf WT, Gerritsen WR, de Klein A, Punt CJ, Figdor CG, Cohen VM, Paridaens D, de Vries IJ. Bol KF, et al. Among authors: de goede al. Ophthalmology. 2016 Oct;123(10):2265-7. doi: 10.1016/j.ophtha.2016.06.027. Epub 2016 Jul 29. Ophthalmology. 2016. PMID: 27476772 Clinical Trial. No abstract available.
Immunological responses to adjuvant vaccination with combined CD1c+ myeloid and plasmacytoid dendritic cells in stage III melanoma patients.
Bloemendal M, Bol KF, Boudewijns S, Gorris MAJ, de Wilt JHW, Croockewit SAJ, van Rossum MM, de Goede AL, Petry K, Koornstra RHT, Figdor C, Gerritsen WR, Schreibelt G, de Vries IJM. Bloemendal M, et al. Among authors: de goede al. Oncoimmunology. 2021 Dec 30;11(1):2015113. doi: 10.1080/2162402X.2021.2015113. eCollection 2022. Oncoimmunology. 2021. PMID: 36524210 Free PMC article. Clinical Trial.
Fully closed and automated enrichment of primary blood dendritic cells for cancer immunotherapy.
Schreibelt G, Duiveman-de Boer T, Pots JM, van Oorschot TGM, de Boer AJ, Scharenborg NM, van de Rakt MWMM, Bos K, de Goede AL, Petry K, Brüning M, Angerer C, Schöggl C, Dzionek A, de Vries IJM. Schreibelt G, et al. Among authors: de goede al. Methods Cell Biol. 2024;183:33-50. doi: 10.1016/bs.mcb.2023.05.008. Epub 2023 Sep 15. Methods Cell Biol. 2024. PMID: 38548417
Insufficient serum caspofungin levels in a paediatric patient on ECMO.
Koch BC, Wildschut ED, Goede AL, Hoog Md, Brüggemann RJ. Koch BC, et al. Among authors: goede al. Med Mycol Case Rep. 2012 Dec 26;2:23-4. doi: 10.1016/j.mmcr.2012.12.006. eCollection 2012 Dec 26. Med Mycol Case Rep. 2012. PMID: 24432208 Free PMC article.
DC immunotherapy in HIV-1 infection induces a major blood transcriptome shift.
de Goede AL, Andeweg AC, van den Ham HJ, Bijl MA, Zaaraoui-Boutahar F, van IJcken WF, Wilgenhof S, Aerts JL, Gruters RA, Osterhaus AD; DC-TRN trial investigators. de Goede AL, et al. Vaccine. 2015 Jun 9;33(25):2922-9. doi: 10.1016/j.vaccine.2015.04.047. Epub 2015 Apr 24. Vaccine. 2015. PMID: 25913415 Clinical Trial.
Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer.
Westdorp H, Creemers JHA, van Oort IM, Schreibelt G, Gorris MAJ, Mehra N, Simons M, de Goede AL, van Rossum MM, Croockewit AJ, Figdor CG, Witjes JA, Aarntzen EHJG, Mus RDM, Brüning M, Petry K, Gotthardt M, Barentsz JO, de Vries IJM, Gerritsen WR. Westdorp H, et al. Among authors: de goede al. J Immunother Cancer. 2019 Nov 14;7(1):302. doi: 10.1186/s40425-019-0787-6. J Immunother Cancer. 2019. PMID: 31727154 Free PMC article. Clinical Trial.
What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings.
Ten Ham RMT, Hövels AM, Hoekman J, Frederix GWJ, Leufkens HGM, Klungel OH, Jedema I, Veld SAJ, Nikolic T, Van Pel M, Zwaginga JJ, Lin F, de Goede AL, Schreibelt G, Budde S, de Vries IJM, Wilkie GM, Dolstra H, Ovelgönne H, Meij P, Mountford JC, Turner ML, Hoefnagel MHN. Ten Ham RMT, et al. Among authors: de goede al. Cytotherapy. 2020 Jul;22(7):388-397. doi: 10.1016/j.jcyt.2020.03.432. Epub 2020 May 12. Cytotherapy. 2020. PMID: 32414635 Free article.
13 results